The purpose of this study was to examine the 24-hour antiischemic effi
cacy of once-a-day anipamil compared to placebo in the treatment of pa
tients with stable angina. The study was designed as a double-blind, p
lacebo-controlled crossover study with an initial 3 week single-blind
placebo period. The patients received anipamil 80 mg once daily, anipa
mil 160 mg once daily, and placebo in a randomized order. At the end o
f each treatment period the patients underwent 24-hour ambulatory ECG
recording. Nineteen patients were included, all with typical stable an
gina pectoris for at least 2 months, exercise test with greater than o
r equal to 0.10 mV horizontal or downsloping ST-segment depression and
limited by angina pectoris, and at least 10 attacks of angina pectori
s in the initial single-blind placebo period. During the placebo perio
d, a total duration of transient myocardial ischemia greater than or e
qual to 0.10 mV during the 24-hour ambulatory ECG monitoring period wa
s 2263 minutes, 75% of which were asymptomatic. Anipamil 80 mg and 160
mg significantly reduced the duration of episodes to 712 minutes (p <
0.001), with 87% asymptomatic, and to 913 minutes (p > 0.001), with 9
2% asymptomatic, respectively. In conclusion, anipamil given once a da
y is an effective 24-hour antiischemic drug in the treatment of transi
ent myocardial ischemia.